# Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine

> **NCT00508261** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 793 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** Meningococcal vaccine GSK134612
- **BIOLOGICAL:** Infanrix™ hexa
- **BIOLOGICAL:** Meningitec™

## Key facts

- **NCT ID:** NCT00508261
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08-01
- **Primary completion:** 2008-05-26
- **Final completion:** 2008-10-27
- **Target enrollment:** 793 (ACTUAL)
- **Last updated:** 2019-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00508261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00508261, "Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00508261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*